Clinical Trials Logo
  1. Home
  2. Severe Asthma
  3. NCT04048343

Long-term Safety of Tezepelumab in Japanese Subjects With Inadequately Controlled Severe Asthma — NOZOMI  

Severe Asthma Clinical Trial

Official title:
A 52-Week, Open-Label, Multicentre Study to Evaluate the Safety of Tezepelumab in Japanese Adults and Adolescents With Inadequately Controlled Severe Asthma (NOZOMI)

Clinical Trial Summary

This is an open-label, single arm study designed to evaluate the safety of tezepelumab administered subcutaneously every 4 weeks in Japanese adult and adolescent subjects with inadequately controlled severe asthma.

Clinical Trial Description

This is open-label, single arm study designed to evaluate the safety of tezepelumab in adults and adolescents with severe, uncontrolled asthma on medium to high-dose ICS and at least one additional asthma controller medication with or without OCS. Approximately 66 subjects will be dosed in Japan. Subjects will receive tezepelumab administered via subcutaneous injection at the study site, over a 52-week treatment period. The study also includes a post-treatment follow-up period of 12 weeks. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04048343
Study type Interventional
Source AstraZeneca
Contact
Status Completed
Phase Phase 3
Start date June 10, 2019
Completion date March 18, 2021
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT05018299 - Evaluate the Efficacy and Safety of FB704A in Adult With Severe Asthma Phase 2
Recruiting NCT05472324 - Evaluate the Efficacy and Safety of TQC2731 Injection in Patients With Severe Asthma. Phase 2
Recruiting NCT04914078 - Severe Asthma Exacerbations and Mepolizumab Treatment
Completed NCT05576454 - Evaluate the Pharmacokinetics of BAT2606 Injection in Healthy Chinese Male Subjects Phase 1
Recruiting NCT04520165 - Effect of Biologicals on Alternative Functions of Eosinophils in Severe Asthma
Recruiting NCT04438408 - National Survey on Care Pathway and Quality of Life in Patients With Severe Asthma According to Their Phenotype.
Not yet recruiting NCT04463836 - Phenotyping Circulating and Lung Resident Eosinophils in Severe Asthma (P-CLESA)
Recruiting NCT03377920 - Predictive Value of Spirometric PIF to Produce PIF Rate Needed for the Use of Current DPI's. N/A
Recruiting NCT04565483 - Predictive Signature of Benralizumab Response Phase 4
Recruiting NCT04045587 - International Severe Asthma Registry: Canadian Cohort
Completed NCT05616338 - Modeling Bronchial Epithelium in Severe Asthma With Human Induced Pluripotent Stem Cells (iPSC) N/A
Active, not recruiting NCT02038374 - Clinico-biological Correlation of Severe Asthma in Children N/A
Active, not recruiting NCT02114034 - Cohort Analysis of Clinical and Biological Severe Childhood Asthma
Recruiting NCT06035289 - Register Schweres Asthma - German Asthma Net e.V.
Not yet recruiting NCT03532685 - Clinical, Inflammatory and Functional Evaluation of a Population of Severe and Obese Asthmatics: Follow up N/A
Completed NCT03931954 - Prevalence of the Eosinophilic Phenotype Among Severe Asthma Patients
Recruiting NCT03984253 - Swiss Severe Asthma Register
Recruiting NCT03435237 - Phenotyping Asthma for Bronchial Thermoplasty
Recruiting NCT03476109 - Study of Magnitude and Prediction of Response to Omalizumab and Mepolizumab in Adult Severe Asthma. Phase 4
Recruiting NCT04714567 - Portuguese Severe Asthma Registry: Getting Answers for Severe Asthma Patients